Neuroimaging and if necessary, genetic testing, can help to confirm an FTD diagnosis.
Eating abnormalities in frontotemporal dementia result from a network of brain regions, rather than 1or 2 specific structures.
Addressing proteasome dysfunction may help prevent accumulation of the toxic protein.
A gene mutation behind a large amount of ALS and FTD cases may disrupt nuclear transport, destroying neurons.
The mouse model will allow researchers to effectively test therapeutic compounds.
The results support the "cognitive reserve" theory that greater mental activity promotes brain connectivity.
C9orf72 hypermethylation helps protect the brain against damage in ALS and frontotemporal degeneration.
Alzheimer's patients had 1.4 times higher concentrations of IAPP than non-Alzheimer's patients in temporal cortex.
The highest dose of intranasal oxytocin seemed to produce the best response.
Neurology Advisor Articles
- New Sleep Apnea Clinical Practice Guidelines
- International League Against Epilepsy Updates Epilepsy Classification System
- In Refractory Status Epilepticus, Lacosamide May Be a Good Option
- Patent Foramen Ovale Closure Reduces Stroke Risk in Patients With Inherited Thrombophilias
- The Handoff: Your Week in Neurology News - 3/23/17
- Q&A: Strategies for Transitioning Pediatric Patients to Adult Care
- Epilepsy Risk May Increase After Incident Depression
- Alzheimer's Caregiver Coping Program Does Not Increase Health Care Costs
- Valproate for Epilepsy Poses Greater Risk for Major Congenital Malformations
- VTE Recurrence Decreased With Rivaroxaban